Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

Shares of Kezar Life Sciences (NASDAQ:KZR) fell 9% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and adopted ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

In a report released yesterday, David S Macdonald from Truist Financial maintained a Buy rating on Concentra Group Holdings Parent, Inc. (CON ...

Shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Get Free Report) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, Ratings reports. One ...

Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...

Shares of Kezar Life Sciences (NASDAQ:KZR) fell 11% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and ...

(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...

After careful consideration and with the assistance of its independent financial and legal advisors, the Board unanimously concluded that the Concentra proposal substantially undervalues the Company.